Skip to content

Premature Atherosclerosis in Systemic Lupus Erythematosus

Premature Atherosclerosis in Systemic Lupus Erythematosus: a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04037293
Acronym
PASLE
Enrollment
500
Registered
2019-07-30
Start date
2013-05-01
Completion date
2021-12-31
Last updated
2019-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, SLE

Keywords

SLE, Atherosclerosis, carotid intima media thickness, brachial-ankle pulse wave velocity, risk factors, Cohort

Brief summary

Patients with SLE have increased rates of atherosclerosis, while the risk factors for atherosclerosis in those patients were not fully revealed. This study is an observational study to investigate the natural process and risk factors for atherosclerosis based on a Chinese SLE cohort. Carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) will be measured for each patient at baseline and 5-year follow-up. Blood tests including cholesterol levels, fasting plasma glucose levels and etc. will also be performed.

Detailed description

Accelerated atherosclerosis is a major complication of systemic lupus erythematosus (SLE), and it leads to increased cardiovascular morbidity and mortality in patients with SLE. Prevention and intervention of premature atherosclerosis is beneficial for prognosis and survival of patients with SLE. The primary aim of this study was to investigate the natural progress of carotid intima media thickness (CIMT) in 5 years, and examine the risk factors for progression of CIMT and atherosclerotic plaques based on a Chinese SLE cohort. The secondary aims of the study were to investigate progression of brachial-ankle pulse wave velocity (baPWV), and to examine the risk factors for increasing baPWV in patients with SLE. Based on sample size calculation, 440 patients who meet the eligibility criteria will be enrolled in this study. All patients will be enrolled from Peking Union Medical College Hospital. After informed consent is obtained, the patients will be comprehensively evaluated from demographic characteristics, medical history, clinical assessments, laboratory tests results, CIMT and baPWV at baseline and 5-year follow-up. Descriptive analysis, univariate analysis, and multivariate analysis will be used to analyze the correlation between potential risk factors and CIMT/baPWV.

Interventions

DIAGNOSTIC_TESTCIMT and baPWV measurement

All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.

Sponsors

Beijing Municipal Science & Technology Commission
CollaboratorOTHER
National Natural Science Foundation of China
CollaboratorOTHER_GOV
Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age≥18 years * Fulfillment of clinical classification criteria of SLE (four or more 1997 American College of Rheumatology classification criteria) * Provision of signed written informed consent

Exclusion criteria

* Clinically overt coronary artery disease * A history of cardiovascular disease (previous stroke, heart failure, myocardial infarction, angina, or symptomatic PAD) * Malignancy * Pregnant/lactating women

Design outcomes

Primary

MeasureTime frameDescription
quantitative change in CIMT from baselineYear 5quantitative changes in CIMT at 5-year follow-up from baseline will be documented

Secondary

MeasureTime frameDescription
quantitative change in baPWV from baselineYear 5quantitative changes in baPWV at 5-year follow-up from baseline will be documented
Major cardiovascular events5 yearsthe prevalence rate of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026